Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy



Similar documents
A Definition of Multiple Sclerosis

What is Multiple Sclerosis? Gener al information

Muscular Dystrophy and Multiple Sclerosis. ultimately lead to the crippling of the muscular system, there are many differences between these

Life with MS: Striving for Maximal Independence & Fulfillment

Multiple Sclerosis (MS)

387

Trauma Insurance Claims Seminar Invitation

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

CBT IN THE CITY. adjusted to the news of being with MS? April Experts at your fingertips call now. Check out our new services in you local area

Multiple Sclerosis: What You Need To Know. For Professionals

Multiple sclerosis (MS)

Cerebral palsy can be classified according to the type of abnormal muscle tone or movement, and the distribution of these motor impairments.

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

AUBMC Multiple Sclerosis Center

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

Webinar title: Know Your Options for Treating Severe Spasticity

Relationship between fatigue, cognitive dysfunction and small fiber neuropathy. Elske Hoitsma

Multiple Sclerosis. Matt Hulvey BL A - 615

Many people with MS use some form of conventional medical treatment, and many people also use complementary and alternative medicine (CAM).

Management in the pre-hospital setting


Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Understanding How Existing and Emerging MS Therapies Work

Clinical features. Chapter 2. Clinical manifestations. Course

Multiple Sclerosis & MS Ireland Media Fact Sheet

New perception of disability including cognition, fatigue, pain and other impairments related to MS

Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

There's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.

OHTAC Recommendation

Clinically isolated syndrome (CIS)

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

Vision Health: Conditions, Disorders & Treatments NEUROOPTHALMOLOGY

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role

Progress in MS: Current and Emerging Therapies

FastTest. You ve read the book now test yourself

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

Multiple Sclerosis Society of Canada. CADA Presentation May 4, 2011

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso

2.1 Who first described NMO?

Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013

Cerebral Palsy. In order to function, the brain needs a continuous supply of oxygen.

AUBAGIO (teriflunomide) oral tablet

CNS DEMYLINATING DISORDERS

Cerebral Palsy , The Patient Education Institute, Inc. nr Last reviewed: 06/17/2014 1

Massage Therapy & Multiple Sclerosis

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

THE SPINAL CORD AND THE INFLUENCE OF ITS DAMAGE ON THE HUMAN BODY

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD

Multiple Sclerosis Ireland, September Contents Summary 2 Commentary 3 Recommendations 5 Information on MS 6 Personal testimonies 9

MULTIPLE SCLEROSIS NURSING INTERNATIONAL CERTIFICATION EXAMINATION

The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central

Treatment of Dysarthria in Patients with Multiple Sclerosis. Barbara Bryant Jane Vyce

ALL ABOUT SPASTICITY. Solutions with you in mind

Neurofibromatosis Type 2: Information for Patients & Families by Mia MacCollin, M.D., Catherine Bove, R.N. Ed. & M. Priscilla Short, M.D.

A Letter From the MS Coalition

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

Transverse Myelitis ISBN A guide for patients and carers

Biogen Idec Contacts: Media: Amy Brockelman (617) Investor: Eric Hoffman (617)

Media Release. Basel, 8 October 2015

GLOBAL SURVEY FACT SHEET

Autoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity

Acute Low Back Pain. North American Spine Society Public Education Series

1: Motor neurone disease (MND)

F r e q u e n t l y A s k e d Q u e s t i o n s

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS

The rising cost of prescription drugs to treat multiple sclerosis in upstate New York

NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute

Chronic Low Back Pain

A Genetic Analysis of Rheumatoid Arthritis

Bell s Palsy ]]> <![CDATA[Bell's Palsy]]>

ARTICLE #1 PLEASE RETURN AT THE END OF THE HOUR

Transcription:

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt ahmed@ahmedhegazi com and ahmedhegazi128@gmail.com www.ahmedhegazi.com

4 rd International Conference and Exhibition on Clinical & Cellular Immunology September 28 30 September, 2015 Houston, USA Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy

It is an Auto Immune Disease which is when the body starts to destroy itself. It is a life-long disease with no cure. In MS, the body attacks and destroys the fatty tissue called myelin that insulates an axon/nerve, and is called demyelination. If damage is severe it can also destroy the nerve/axon itself. MS affects the central nervous system and inflames the white matter in the brain which creates plaques..

Definition of Multiple Sclerosis An inflammatory demyelinating disease of the CNS where there is: Dissemination in space Dissemination in time No alternative neurologic disease MS is a clinical diagnosis

Multiple Sclerosis Epidemiology The most common progressive neurologic disease of young adults Affects 350,000 persons in the USA Risk Factors: Female sex White race Northern latitude (USA) High socioeconomic status Scandinavian ancestry

MULTIPLE SCLEROSIS FEATURES two stages disease: inflammation and neurodegeneration 4,000,000 people affected worldwide Women:men 2:1 Age of disease onset: 25-30 ys (young adulthood)

Neurological impairments: blindness, loss of sensation, lack of coordination, incontinence, paralysis Relapsing-remitting (80%); chronic progressive (10%); benign (10%)

Disease Overview: Autoimmunity Peripheral tolerance involves a populations of regulatory T cells which maintain autoreactive T cells in a dormant state in the circulation in adults. P. Martini

The autoreactive T cells can be awoken from this state by local or environmental stimuli such as exposure to endogenous or exogenous antigens in the circulation. In MS these cells becomes activated either because of failure of the mechanism of peripheral tolerance or due to priming by antigens.

MULTIPLE SCLEROSIS FEATURES Once activated autoreactive T cells release a cocktails of cytokines that are important for migration and homing of the cells to the target sites and for initiation of the inflammatory process

Disease Overview: Multiple Sclerosis Multiple Sclerosis (MS) is an inflammatory disease of the Central Nervous System (CNS) affecting the brain and spinal cord. Predominantly, it is a disease of the "white matter" tissue. The white matter is made up of nerve fibers which are responsible for transmitting communication signals both internally within the CNS and between the CNS and the nerves supplying rest of the body.

Multiple Sclerosis Etiology Possible precipitating factors include Infection Physical injury Emotional stress Excessive fatigue Pregnancy Poor state of health

Multiple Sclerosis Etiology and Pathophysiology Myelin can be replaced by glial scar tissue Without myelin, nerve impulses slow down With destruction of axons, impulses are totally blocked Results in permanent loss of nerve function

Signs & Symptoms : The person with MS can sufferalmost any neurological symptom or sign, including: changes in sensation, muscle weakness, spasm, or difficulty in moving; difficulties with coordination and balance;

Signs & Symptoms : problems in speech or swallowing, visual problems, fatigue, pain bladder and bowel difficulties. Cognitive impairment of varying degrees emotional symptoms of depression or unstable mood are also common.

Symptoms of MS Fatigue Depression Memory change Pain Spasticity Vertigo Tremor Double Vision/Vision Loss Weakness Dizziness/Unsteadiness Numbness/Tingling Ataxia Euphoria Speech disturbance Bladder/Bowel/Sexual dysfunction

Causes Of MS : Most likely MS occurs as a result of some combination of genetic, environmental and infectious factors. Epidemiological studies of MS have provided hints on possible causesforthedisease.

Theories try to combine the known data into plausible explanations, butnonehasproveddefinitive. Genetics: Environmental factors: Infections:

Genetics Of MS

Radiological Findings

Magnetic Resonance Imaging in MS Spinal cord Optic nerve Brain

Brain Atrophy (Shrinkage) in Untreated MS Images acquired over the course of 7 years from a single person with untreated MS

MRI: Spinal Imaging

Eighty patients known to be with MS, Twenty four males and fifty six females, their ages ranged between 26-71 years, with a mean of 38.7 ±4.8. 2.

All cases were subjected to complete clinical and neurological history and examination to confirm the diagnosis.

There were 44 cases with quadriparesis, (12 males and 32 female) and 36 cases with paraparesis (12 males and 24 females).

All cases were under their regular treatment either by corticosteroids,orinterferon. These cases were divided into two main groups, each group consists of 40 cases (12 males and 28 females),

Group I received honey, pollen, royal jelly and propolis and were treated with bee acupuncture 3 times weekly, for 12 months, started gradually by one sting then gradually increase up to 25 stings per session, in addition to their medical treatment

while group II remains on their ordinary medical treatment only.

Bee acupuncture done by bee stings for regulating the immunesystem in thefollowing points Du 13, 14, Li 11, S6, S9, points for MS Pat Wagner Buttocks Jiagi points forcervical area and lumber area and vision pointsgb2and Li3.

All patients were instructed to receive 2000-3000 mgvitaminc, 15 mgvit. B1, 3 mgvit. B2, 2mgVit. B6, 5 mgvit. B12,

25 mg Folicacid, 3 mg Calciumpantothenate, 15mg Nicotinamide, 20 mg L-Arginine, 20 mg L- Lysine and 3 mcg Biotin/day.

Serum samples were obtained from patients with clinically definite MS for estimation of serum levels of immunoglobulin E (Hiranoet al., 1989) using commercially available ELISA kits according to the manufacturers' directions.

Serum cytokine levels IFN-γ, interleukin (IL) 1β, IL-4, IL-6, IL-10, tumor necrosis factor alpha (TNFα) were assessed using enzyme inked - immunosorbent assays (Abrams, 1995) using commercially available ELISA kits according to the manufacturers' directions (kits produced by Bender Med System, Vienna, Austria).

All these investigations were done at the beginning of the study and by the end of one year of supplementation and bee sting sessions

Wefound that8patients outof 12 (66.6 %of paraparesiscases), showed some improvement regarding theirdefectsingait, bowelcontrol, constipation andurination,

while 12 cases out of 16 cases (75% of quadriparesis cases), showed some mild improvement in their movement in bed, and better improvement in bed sores, sensation, and better motor power, only two cases of them ( 12.5% ) were able to stand for few minutes with support.

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Symptoms Score Improvement Recorded Every Two Months (1-12):

Mean levels of IgE of both groups at the start and end of the study

Mean levels of (TNF) αof both groups at the start and end of the study

Mean levels of (IL) 1βof both groups at the start and end of the study

Mean levels of IL-6 of both groups at the start and end of the study

Mean levels of (IL 4) of both groups at the start and end of the study

Mean levels of IL-10 of both groups at the start and end of the study

Although Apitherapy is not a curable therapy in MS, but it can be used to minimize some of the clinical symptoms of MS, and can be included amongprogramsof MS therapy.

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmed G. Hegazi National Research Center, Egypt

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmed G. Hegazi National Research Center, Egypt

Prof. Dr. Ahmed Hegazi Professor of Microbiology and Immunology National Research Center, Dokki, Giza, Egypt President of Egyptian Environmental Society for uses and production of bee products Secretary of Egyptian Society of Apitherapy Secretary General of African Federation of Apiculture Associations Member of Apitherapy Commission, APIMONDIA E mail: ahmed@ahmedhegazi.com and ahmedhegazi128@gmail.com www.ahmedhegazi.com Tel: + 2023 7749222 and + 20238860682 Fax: + 202 37749222 and + 202 33370931 GMS: + 201001440063